Dayvigo (Lemborexant) Adolescent Safety: What Parents and Clinicians Need to Know About Ages 12 to 17

FDA Approval Status and Why Adolescent Use Remains Off-Label

Lemborexant received FDA approval in December 2019 for the treatment of insomnia in adults, based on the SUNRISE clinical trial program. The labeled indication covers patients 18 years and older. No pediatric supplement or expanded indication has been granted.

The FDA-approved prescribing information states that "safety and effectiveness in pediatric patients have not been established" [1]. This language means the agency has not reviewed controlled data supporting use below age 18. Off-label prescribing is legal and sometimes clinically reasonable, but it shifts the evidence burden entirely onto the treating clinician.

Eisai registered a pediatric pharmacokinetic/safety study (ClinicalTrials.gov NCT04128553) for lemborexant in participants aged 2 to 17 with insomnia disorder. As of May 2026, no peer-reviewed efficacy results from this trial have been published. The Pediatric Research Equity Act (PREA) requires manufacturers of new molecular entities to submit pediatric study plans, and Eisai has a PREA commitment on file. Until those data mature, any adolescent prescription relies on adult trial extrapolation and clinical judgment.

What SUNRISE-1 Showed in Adults and How It Might Apply to Teens

The SUNRISE-1 trial (N=1,006) randomized adults aged 55 and older with insomnia to lemborexant 5 mg, 10 mg, zolpidem ER 6.25 mg, or placebo for one month [2]. Both lemborexant doses significantly reduced latency to persistent sleep measured by polysomnography. The 5 mg dose cut sleep onset latency by a mean of 10.5 minutes more than placebo (P<0.001), and the 10 mg dose by 12.5 minutes more than placebo (P<0.001) [2].

SUNRISE-2 extended these findings over 12 months in adults aged 18 to 88, confirming durability without evidence of rebound insomnia on discontinuation [3]. Neither trial enrolled anyone under 18.

Extrapolating adult efficacy data to adolescents is common in sleep medicine but imperfect. Adolescent sleep architecture differs from adult patterns: slow-wave sleep percentage is higher, circadian phase is delayed, and the homeostatic sleep drive operates differently during puberty [4]. These biological differences mean that a drug working through orexin receptor blockade may produce distinct effect sizes, onset profiles, or side-effect patterns in a 14-year-old compared to a 60-year-old. Pharmacokinetic modeling from Eisai's Phase I program suggests that body-weight-adjusted exposures at the 5 mg dose in adolescents are within the range observed in adults, but exposure matching does not guarantee equivalent safety or efficacy.

The Orexin System in the Developing Adolescent Brain

Orexin-A and orexin-B (also called hypocretin-1 and hypocretin-2) are neuropeptides produced by a cluster of roughly 70,000 neurons in the lateral hypothalamus [5]. They regulate wakefulness, arousal, appetite, reward processing, and sympathetic tone. Lemborexant blocks both OX1R and OX2R receptors, suppressing the wake-promoting signal so sleep can occur.

In adolescents, the orexin system is still maturing. Animal studies show that orexin neuron projections to the prefrontal cortex undergo pruning and remodeling through late adolescence [6]. Blocking these receptors during a period of active neurodevelopment raises theoretical concerns that do not apply to the same degree in adults.

No human study has directly measured the effect of chronic DORA exposure on adolescent brain maturation. This is the single biggest knowledge gap. The concern is theoretical rather than demonstrated, but it cannot be dismissed either. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for chronic insomnia recommends CBT-I as first-line therapy for all ages and explicitly notes the limited pharmacotherapy evidence base in pediatric populations [7].

Known Side Effects from Adult Data and Adolescent-Specific Risks

The most common adverse reactions in adult SUNRISE trials were somnolence (reported by 10% at 10 mg vs. 1% placebo), headache (6% vs. 4%), and dizziness (3% vs. 1%) [1]. Sleep paralysis occurred in approximately 1% of patients on lemborexant 10 mg [1]. Cataplexy-like symptoms were rare but documented.

For adolescents, several risks deserve special attention.

Next-day somnolence and academic performance. A teenager experiencing residual drowsiness at 7 a.m. Faces consequences that differ from those of a retired adult. Driving to school, athletic participation, and classroom concentration all depend on full next-morning alertness. The FDA label carries a next-morning impairment warning and advises against driving until the patient knows how the drug affects them [1].

Suicidal ideation. The FDA requires a class-wide warning for all DORAs regarding worsening depression and suicidal ideation [1]. Adolescents already face elevated baseline rates of suicidal thinking. A 2022 CDC Youth Risk Behavior Survey found that 22% of U.S. High school students seriously considered suicide in the preceding 12 months [8]. Adding a CNS-active medication with a suicidality warning demands structured screening at baseline and at every follow-up, using validated tools such as the Columbia Suicide Severity Rating Scale (C-SSRS).

Growth velocity. Orexin signaling interacts with growth hormone secretion. Growth hormone release peaks during slow-wave sleep, and orexin neurons modulate hypothalamic growth-hormone-releasing hormone (GHRH) pathways [5]. No clinical data exist on whether lemborexant alters growth velocity in adolescents, but monitoring height and weight at 3-month intervals is a reasonable precaution for any teen on a chronic sleep medication.

Weight and appetite. Orexin-A stimulates feeding behavior through lateral hypothalamic circuits. Blocking this signal could theoretically suppress appetite or alter metabolic rate. Adult SUNRISE data did not show clinically significant weight changes, but adolescent metabolic demand during growth spurts is fundamentally different.

How Lemborexant Compares to Other Sleep Medications Used Off-Label in Teens

No FDA-approved pharmacotherapy for adolescent insomnia currently exists. Every medication prescribed for teen insomnia is off-label. The question is not whether off-label use is acceptable but which agent carries the best risk-benefit profile.

Melatonin is the most commonly used sleep aid in adolescents. A 2022 Cochrane review of melatonin for sleep problems in children and adolescents found modest improvements in sleep onset latency (mean reduction 22.4 minutes vs. Placebo across 7 RCTs, N=387) with minimal adverse effects [9]. Melatonin does not carry suicidality warnings, has no DEA scheduling, and costs a fraction of lemborexant.

Suvorexant (Belsomra), the other commercially available DORA, is also approved only for adults. It shares the same class-wide warnings. One advantage lemborexant may hold over suvorexant is a shorter half-life (approximately 17 hours vs. 12 hours for suvorexant), which could mean less next-day residual sedation, though this has not been tested head-to-head in adolescents [10].

Trazodone is widely prescribed off-label for adolescent insomnia despite thin evidence. A 2020 systematic review in the Journal of Clinical Sleep Medicine found no randomized controlled trials of trazodone for pediatric insomnia [11]. It is prescribed based on sedation as a side effect, not on insomnia-specific trial data.

Benzodiazepine receptor agonists (zolpidem, eszopiclone) carry FDA warnings against pediatric use due to psychiatric adverse events and have stronger abuse potential than DORAs.

Given this field, lemborexant is not a first-choice, second-choice, or even third-choice agent for most adolescents with insomnia. CBT-I remains the starting point. Melatonin is the most studied pharmacologic option. Lemborexant enters consideration only when these approaches have failed and the insomnia is causing significant functional impairment.

Monitoring Protocol If Lemborexant Is Prescribed Off-Label to a Teen

If a clinician, after exhausting behavioral and first-line options, prescribes lemborexant to an adolescent, a structured monitoring protocol reduces risk.

Before starting. Screen for depression and suicidal ideation using the PHQ-A (Patient Health Questionnaire for Adolescents) and C-SSRS. Document height, weight, and Tanner stage. Obtain a baseline sleep diary spanning at least two weeks. Confirm that CBT-I has been attempted for a minimum of 6 to 8 sessions per AASM guidelines [7]. Rule out obstructive sleep apnea, restless legs syndrome, delayed sleep-wake phase disorder, and medication-induced insomnia.

Dose selection. Start at 5 mg. The adult label allows uptitration to 10 mg, but in adolescents the lower dose should be maintained unless there is no response after 4 weeks and the patient tolerates 5 mg without next-day impairment. The 10 mg dose produced roughly double the somnolence rate in SUNRISE-1 compared to 5 mg [2].

Follow-up schedule. Week 2: phone or telehealth check for somnolence, mood changes, parasomnias, and sleep paralysis. Week 4: in-person visit with C-SSRS, sleep diary review, and academic function assessment. Month 3 and every 3 months after: height, weight, C-SSRS, sleep diary. Reassess the need for continued therapy at 6 months. The goal is the shortest effective treatment duration.

Discontinuation. SUNRISE-2 showed no rebound insomnia in adults upon abrupt discontinuation after 12 months of use [3]. The prescribing information does not require tapering. For adolescents, a gradual reduction (e.g., alternating nights for 1 to 2 weeks) may still be psychologically helpful and avoids any theoretical risk of sleep disruption during a period when academic or social stressors peak.

As Dr. Judith Owens, director of the Center for Pediatric Sleep Disorders at Boston Children's Hospital, has noted: "The single most important principle in pediatric sleep pharmacology is that medications should be time-limited and always paired with behavioral intervention."

Drug Interactions Relevant to Adolescents

Lemborexant is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, certain HIV protease inhibitors) are contraindicated because they can triple lemborexant plasma levels [1]. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil) require dose reduction to 5 mg maximum.

For adolescents specifically, two interaction categories matter most.

Hormonal contraceptives. Many combined oral contraceptives are weak CYP3A4 inhibitors. The clinical significance of this interaction with lemborexant has not been studied, but awareness is appropriate for female adolescents on birth control.

SSRIs and SNRIs. Fluoxetine and fluvoxamine are moderate-to-strong CYP inhibitors. Fluvoxamine is a potent CYP3A4 inhibitor, and co-prescribing with lemborexant should be avoided. Fluoxetine primarily inhibits CYP2D6 but has modest CYP3A4 effects. Given that approximately 15% of U.S. Adolescents aged 12 to 17 have used an antidepressant in the past month according to NCHS data [12], this interaction is not hypothetical.

Alcohol and cannabis. Both are CNS depressants. The FDA label warns against concurrent alcohol use [1]. Cannabis, particularly THC, is a CYP3A4 substrate and potential inhibitor. Adolescent cannabis use rates are high enough that clinicians should ask directly about consumption before prescribing any DORA.

What the AASM and AAP Recommend for Adolescent Insomnia

The AASM 2023 clinical practice guideline for chronic insomnia recommends CBT-I as first-line treatment and rates the evidence for pharmacotherapy in pediatric populations as insufficient to make strong recommendations [7]. The American Academy of Pediatrics (AAP) has echoed this position, stating in its 2022 technical report on adolescent sleep: "Pharmacologic agents should be reserved for cases where behavioral interventions have been implemented and have proven insufficient, and should be prescribed at the lowest effective dose for the shortest possible duration."

These are not vague suggestions. They reflect the reality that no sleep medication has an FDA-approved pediatric insomnia indication and that long-term developmental safety data are absent across the entire drug class, DORAs included.

The AASM guideline also highlights the importance of addressing sleep hygiene and circadian factors before considering any medication. Delayed sleep-wake phase disorder is common in adolescents due to biological circadian shifts during puberty. Strategic light exposure therapy and chronotherapy may resolve what appears to be insomnia without any pharmacologic intervention [7].

The Risk-Benefit Calculation for Adolescent Lemborexant Use

Severe, treatment-resistant adolescent insomnia causes real harm. Academic failure, depression, motor vehicle accidents (teen drivers are already at disproportionate crash risk), and metabolic disruption all worsen with chronic sleep deprivation. A 2018 meta-analysis published in JAMA Pediatrics (N=41 studies, 285,270 adolescents) found that short sleep duration was associated with a 58% increased odds of suicidal ideation and a 47% increase in suicide attempts [13].

When insomnia is this consequential and CBT-I plus melatonin have failed, the risk of untreated insomnia may exceed the risks of a carefully monitored trial of lemborexant 5 mg. That calculation must be individualized, documented in the medical record, and discussed with both the adolescent and their parent or guardian.

The monitoring burden is real. Quarterly C-SSRS assessments, growth tracking, and sleep diary reviews require clinic time. But the alternative, a teenager accumulating sleep debt night after night, carries its own compounding risks.

Clinicians initiating off-label lemborexant in an adolescent should document the following in the chart: failure of CBT-I (number of sessions, provider), failure of melatonin (dose tried, duration, response), rationale for lemborexant over other agents, informed consent discussion including the off-label nature and class-wide suicidality warning, and a specific re-evaluation date no more than 6 months out.